Data for this Review were identified by a search of the National Library of Medicine (PubMed) by use of the search terms: “renal-cell carcinoma,” “renal carcinoma” or “kidney cancer”, and “targeted therapy” with further limits defined as adult human studies and core clinical journals in English. Only papers published since 1980 were considered. 472 articles were retrieved. We then further refined this list by excluding review articles that did not directly address resistance. We also
ReviewResistance to targeted therapy in renal-cell carcinoma
Introduction
Renal-cell carcinoma (RCC) is a disease characterised by highly vascular tumours (figure 1). Therapy targeted at the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways now represents the standard of care in metastatic RCC. Each of these approaches offers significant clinical benefit, as measured by objective responses, reduction in tumour burden, and prolongation of progression-free or overall survival compared with previous therapeutic standards. However, complete or durable responses have been only rarely noted, necessitating chronic therapy for most patients. Furthermore, treatment has typically been associated with the development of resistance after a median of 6–15 months of treatment. Sequential use of these agents has become the empirical standard of care, with activity seen even when using an agent with a similar target after disease progression on a previous therapy. Thus, a pressing clinical and scientific question arises about the mechanism(s) of resistance to VEGF-targeted and mTOR-targeted therapy, and the optimum treatment approach for patients with metastatic RCC in this setting. Emerging clinical and preclinical data are available to address this issue. In this Review, we summarise the existing data that provide insight into this issue, and discuss methodological issues for drug investigation in this setting.
Section snippets
Mechanism of action of existing therapy
The pathogenesis of RCC identifies the VEGF and mTOR pathways as relevant therapeutic targets. RCC is characterised by inactivation of a crucial tumour-suppressor gene, known as von Hippel Lindau (VHL).1, 2 VHL encodes the VHL protein, which is a component of an E3 ubiquitin–ligase complex that targets a transcription factor, hypoxia-inducible factor (HIF), for proteasome-mediated degradation (figure 2). If VHL is inactivated, a defective VHL protein is produced and HIF is not degraded.
Insights into mechanisms of resistance
Although in some malignant diseases (eg, lung cancer and chronic myeloid leukaemia) the development of resistance to a targeted therapy (eg, erlotinib or imatinib) is often due to a mutation in a gene encoding a key receptor tyrosine kinase targeted by the drug,17, 18, 19, 20 this mechanism seems to be an unlikely explanation for the development of resistance to VEGF-pathway antagonists. Because the main target for VEGFR inhibitors resides on endothelial cells, a mutation conferring treatment
Clinical definition of resistance
In view of the fact that many treatment options for metastatic RCC now exist, it is important to not only maximise current therapy, but also to realise when the treatment benefit has ended so that subsequent therapy can be considered. Resistance to or failure of antiangiogenic agents is currently defined by the evidence of disease progression according to RECIST criteria despite therapy. This progression is defined as an increase of 20% or more in the sum of measurable lesions, the appearance
Investigative strategies for overcoming resistance
Several strategies emerge from the above considerations regarding resistance mechanisms to currently available therapeutics in RCC. The first involves the use of an agent that blocks a resistance mechanism. Such an agent could be used as monotherapy at the time of resistance to targeted therapy, could be added to continued VEGF blockade at the time of resistance, or could be added initially in combination with VEGF blockade with the hope of delaying the onset of resistance. Alternatively, more
Conclusions
Despite the reliance of renal carcinoma cells and surrounding stroma on elements of the VEGF and mTOR pathways, the inability to sustain initial tumour stabilisation or regression induced by VEGF-pathway or mTOR-pathway blockade is a significant clinical issue. Existing evidence suggests that resistance to VEGF blockade is related to re-establishment of angiogenesis, but does not provide a clear and unique mechanism. Clinical data showing efficacy of dose increases or alternate (probably more
Search strategy and selection criteria
References (54)
- et al.
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Lancet Oncol
(2007) - et al.
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Clin Genitourin Cancer
(2007) - et al.
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood
(2007) - et al.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Cancer Cell
(2002) - et al.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Lancet
(2008) - et al.
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Cancer Cell
(2005) - et al.
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
Cell
(2007) - et al.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Lancet
(2007) - et al.
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Cancer Cell
(2004) - et al.
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Eur J Cancer
(2009)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
Mol Cell
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2
J Biol Chem
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Blood
Identification of the von Hippel-Lindau disease tumor suppressor gene
Science
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis
Genes Chromosomes Cancer
Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells
J Clin Invest
Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(−/−) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
Proc Natl Acad Sci USA
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Clin Cancer Res
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Cancer Res
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy
AJR Am J Roentgenol
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Radiology
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
J Clin Invest
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
J Urol
Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
J Clin Oncol
Modes of resistance to anti-angiogenic therapy
Nat Rev Cancer
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Nat Med
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Med Oncol
Cited by (489)
N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential
2023, Biochimica et Biophysica Acta - Gene Regulatory MechanismsSunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
2023, Drug Resistance UpdatesEstablished and emerging biomarkers of immunotherapy in renal cell carcinoma
2024, Immunotherapy